N/A N=14 Meibomian Gland Dysfunction Treatment
Meibomian Gland Dysfunction · Dry Eye
Primary: Dry Eye Questionnaire 5 (DEQ-5) Score — 11.8; 11.8 score on a scale — p=0.02
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=139 Treatment of Meibomian Gland Dysfunction and Evaporative Dry Eye
Chalazion · Dry Eye Syndromes
Primary: Meibomian Gland Assessment (Total Meibomian Gland Secretion Score) — 6.3; 5.6; 14.3; 6.1 Scores on a scale
Phase 3 N=50 Evaluation of Screening Methods for Treatment of Meibomian Gland Dysfunction
Chalazion · Dry Eye Syndromes
Primary: Association Between Screening Methods (Meibomian Gland Expression) and Treatment Effectiveness Outcomes (Total Meibomian Gland Score) — 0.4816 Correlation coefficient…
N/A N=69 The Efficacy of an Ocular Emulsion in Meibomian Gland Dysfunction
Meibomian Gland Dysfunction
Primary: Tear Film Breakup Time — 4.65; 4.42 seconds — p=0.550
N/A N=55 Treatment of Meibomian Gland Dysfunction and Dry Eye in Contact Lens Wearers
Meibomian Gland Dysfunction · Dry Eye
Primary: Mean Change in Meibomian Gland Score From Baseline at 3 Months — 12.4; 1.4 units on a scale — p=<0.0001
N/A N=34 Treatment of Meibomian Gland Dysfunction Prior to Cataract Surgery
Blepharitis · Dry Eye Syndrome
Primary: Mean Change in Total Meibomian Gland Score — 12.8; 1.9 Change in Meibomian Gland Score
N/A N=19 Intense Pulse Light Treatment With Meibomian Gland Expression of the Upper Eyelids in Dry Eye Disease
Dry Eye
Primary: Non-invasive Tear Break up Time (TBUT) — 3.9; 4.0 seconds
N/A N=62 Contact Lens Comfort Relative to Meibomian Gland Status
Meibomian Gland Dysfunction
Primary: Comfort as Measured by the Contact Lens Users Experience Questionnaire (CLUE) — 58.67 units on a scale
Phase 4 N=45 Intraductal Meibomian Gland Probing Trial
Meibomian Gland Dysfunction
Primary: Ocular Surface Disease Index (OSDI) — 38.7; 36.9; 37.3 units on a scale
N/A N=39 Meibography and Tear Scan Using the Oculus Keratograph 4
Meibomian Gland Dysfunction
Primary: Meibomium Gland Dropout Score - Evidence of Meibomian Gland Dysfunction (MGD) Confirmed by Meibograhpy Imaging Using the Keratograph 4 Measured on a Subjective Grading…
N/A N=30 iLux Treatment for Meibomian Gland Dysfunction (MGD)
Evaporative Dry Eye
Primary: Change From Baseline in Meibomian Gland Secretion (MGS) Total Score — 12.3; 14.5 score on a scale — p=<0.0001
Phase 4 N=31 Lipids of the Human Tear Film and Their Effect on Tear Stability
Blepharitis
Primary: Global Response to Therapy — 16; 41 eyes — p=.001
Phase 2 N=232 A Study of AGN-195263 for the Treatment of Meibomian Gland Dysfunction
Meibomian Gland Dysfunction
Primary: Percentage of Meibum Quality Responders in the Study Eye — 46.3; 33.9; 32.1; 42.9 Percentage of Patients
Phase 2 N=31 Evaluation of AZR-MD-001 in Patients With Meibomian Gland Dysfunction (MGD)
Meibomian Gland Dysfunction
Primary: Meibum Gland Secretion Score (MGS) — 0.5; 7.4 score on a scale
N/A N=21 Evaluate the Safety and Effectiveness of The Tixel Fractional System in the Treatment of Meibomian Gland Disfunction
Dry Eye Syndromes · Dry Eye · Meibomian Gland Dysfunction
Primary: Score and Change From Baseline in Tear Break Up Times (TBUT), as Assessed by a Masked Rater — 4.0; 1.9; 3.4; 4.7 seconds
N/A N=57 Safety and Efficacy of TrueTear™ for the Treatment of Meibomian Gland Disease
Meibomian Glands · Dry Eye Syndromes
Primary: Change From Baseline in Meibomian Gland Dysfunction (MGD) Impact Questionnaire Score — -0.4; -0.3; -0.4; -0.2 score on scale — p=0.9788
N/A N=109 to Evaluate the Effectiveness and Safety of the Tixel® , VS LipiFlow® in the Treatment of Meibomian Gland Dysfunction
Meibomian Gland Dysfunction · Dry Eye Syndromes · Dry Eye
Primary: Changes in Tear Break Up Times (TBUT) to the 4-weeks Follow-up Exam — 4.3; 4.6; 3.0; 2.7 seconds
N/A N=142 Comparison Between iLux™ and LipiFlow® in the Treatment of Meibomian Gland Dysfunction
Meibomian Gland Dysfunction
Primary: Change From Baseline to Week 4 in Meibomian Gland Score (MGS) — 17.3; 18.0; 17.7; 18.1 score on a scale
Phase 2 N=205 Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease
Blepharitis
Primary: Change From Baseline in Ocular Discomfort — -4.1; -2.4 score on a scale
N/A N=35 Comparison of Lipiflow®-Treatment and a Standard Lid Hygiene Regime
Meibomian Gland Dysfunction
Primary: Change of Dry Eye Symptoms — 40.1; 46.2; 39.7; 15.9 units on a scale
Phase 2 N=60 Safety and Efficacy Study of a Testosterone Eye Drop for the Treatment of Meibomian Gland Dysfunction
Meibomian Gland Dysfunction
Primary: Meibomian Gland Secretion Appearance at Visit 4 (Day 168) — 0.80; 0.96 units on a scale
N/A N=26 SYSTANE® Family - Meibomian Deficiency
Dry Eye Syndrome
Primary: Number of Meibomian Glands Yielding Liquid Secretion (MGLYS) — 3.5; 4.2; 7.0; 3.9 functioning glands
Phase 2 N=95 Safety, Efficacy and Pharmacokinetics of CBT-008 in Patients With Meibomian Gland Dysfunction
Meibomian Gland Dysfunction
Primary: IOP Related to Safety — 15.906; 16.452; 16.469 mmHg
Phase 3 N=32 Methods to Enhance AZR-MD-001 for Meibomian Gland Dysfunction (MGD)
Meibomian Gland Dysfunction
Primary: Primary Efficacy for MGD: Change From Baseline to Month 3 in Meibomian Gland Secretion Score (MGS) — 12.8; 8.8 Units on the MGS Scale
N/A N=200 Randomized Controlled Trial of Long-term Treatment Effectiveness for Meibomian Gland Dysfunction (MGD) and Dry Eye
Meibomian Gland Dysfunction · Dry Eye
Primary: Stage 1 Mean Change in Total Meibomian Gland Score From Baseline to 3 Months — 11.6; 4.5 units on a scale — p=<0.0001
N/A N=20 Efficacy of IPL Treatment of Dry Eye and Ocular Rosacea
Ocular Rosacea · Dry Eye
Primary: Change in Ocular Surface Disease Index (OSDI) Symptom Survey Score — -25.9; -2.0 percentage of change in OSDI score — p=0.0312
N/A N=150 Chalazion Conservative Treatment Trial
Chalazion Unspecified Eye, Unspecified Eyelid · Chalazion Left Eye, Unspecified Eyelid · Chalazion Right Eye, Unspecified Eyelid
Primary: Number of Participants With Complete Resolution — 13; 12; 11 participants
N/A N=88 Effectiveness of Intense Pulsed Light for Improving Dry Eye Syndrome
Dry Eye Syndrome
Primary: Change of Baseline Tear Breakup Time (TBUT) — 0.75; 1.99 seconds
N/A N=8 IPL and Meibomian Gland Expression to Treat Ocular Rosacea Ocular GVHD
GVHD · Ocular Rosacea · Dry Eye Syndrome
Primary: Number of Participants Who Responded to Intense Pulsed Light (IPL) — 5; 2 participants
Phase 2 N=129 Evaluation of AXR-270 for the Treatment of Posterior Blepharitis Associated With Meibomian Gland Dysfunction
Posterior Blepharitis · Meibomian Gland Dysfunction
Primary: Adverse Events — 1; 1; 2; 0 adverse events